Member Info for chester18

Oh and i forgot the Exosome platform...

So much to remember......LOL

Hi PC01,

the Woodford debacle certainly knocked the share price when it should have stabilized around the £3.00 mark.
Even at todays price we are still only valued at £76M when the Fosun deal starting blocks are going to be worth £80M + Cash in the Bank + CTX ( Pisces lll Trial ) + Retinitis Pigmentosa (RP Trial).
Certainly in for a rollercoaster of a ride going towards 31st October and beyond.

Chester.

Could be ' PISCES III ' ,
first patient enrolled on 24th January 2019 with data to be measured at 6 months and Top Line Data at 12 months.
So could be that there is some significant data at 6 months ready to announce.

"ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that the first patient has been treated in the US Phase IIb clinical study of the Company's CTX cell therapy candidate for stroke disability.
The study, designated PISCES III, is a randomised, placebo-controlled clinical trial involving 110 patients across 40 clinical trial sites in the US. Patients with stable post-stroke disability are entered into the study 6 to 12 months after their stroke and are randomised to receive either the CTX therapy or placebo treatment.
The primary end-point of the study is a comparison of the proportion of patients in the treated and placebo arms showing a clinically significant improvement on the Modified Rankin Scale, a measure of disability and dependence, at 6 months post-treatment compared with baseline. Top-line results from the study are expected in early 2020".

Just a guess but fits the timescale.

Chester.

I am confident that this is something new. Its either a deal is imminent or there is a rumour going round that there is a deal happening. Or something very positive has happened in the trials. You don't see these levels of buying without a very good reason. Pretty exciting time to hold Rene shares....

Chester.

Looks like there are a few buyers out there who have done some homework and like what they see in Reneuron.
I know you can't always tell exactly what are buys or sells but roughly added there were £42k worth of sells and £94.5k of buys.

It's not a massive chunk of the shares changing hands but it's a 2-1 positive sign.

Let's hope the SP continues in an upward direction as we start to get closer to October's news.....

Chester.

Thank you for your reply's,

I asked that earlier question because due to the FDA hold up we've been treading water on the SCIB 1 / Combo front for 12 months and we could have had very valuable data in our hands by now if the US trail had started in Jan 2019.
I do realise during that time we have been pushing on with the MODI platform, but I get the sense that big pharma are getting very aggressive in the Cancer - Immunotherapy area. When a deal goes through like "Immatics scores $75M upfront in TCR deal with Celgene, with possible $550M to follow", it makes me ask, "are we being overtaken due to our lack of clinical data". After all big pharma has way more resources at their disposal to speed things up.

So your answers tell me, that although these other teams have science that looks promising, in the main they all have to prove their theoretical science against a specific antigen and its the antigen that they are still trying to find and engage, which may take a year or years to achieve.
Therefore the data from the future MODI 1 Trial is going to have the Cancer - Immunotherapy scientific community on the edge of their seats and Big Pharma reaching for their wallets. Now that is the scenario that I sit on the edge of my seat and dream about. As we keep being told 'its all about the data'.

Chester.

Hi Inanaco

Question for you...

In your opinion, the deals that we have recently seen happen in the TCR or Immuno space:
Are these companies all well ahead of us or are the deals being done based on 1, 2 or 3 years ahead?

In other words are we in this race at the front or at the back?

Chester.

Hi C7

Mucho congratulations on a well battled three points..

With regards to the FDA it still intrigues me what can be so wrong (in the FDA's opinion) with Ichor’s device that it has taken over twelve months to find the solution to the problem.

If the device has gone through the European / UK process without there being any objections surely the FDA could have considered why it passed over here.

It is very bewildering.....

Chester.

We have definitely just had a very interesting week. Of all the speculations of why we had not started the UK arm of the trial, none of us thought that the permission to start was linked to the FDA / IND. So it turns out that the UK arm formed a part of the US trial but now when the FDA finally pass TriGrid 2 the US arm will form a part of the UK trial.

Being a long term shareholder with Scancell is not without its surprises. Just shows that we only know a fraction of what's potentially coming next.

So with my very dusty crystal ball I'm looking forward to news this week that we have finally started the trial and started the process towards the much anticipated trial data.

At some point very soon we should be out of the wilderness for good.

Chester.

Well if you were wondering how the trials are doing here is a very large hint......
These renowned scientist have not put their names against fresh air.
Also, strongly indicates that other conditions are being investigated for the future pipeline.

All very very positive.

Chester.

That one trade tells me that someone sees today news as a green light. If there is a "First Patient Dosed" RNS in the next week then we know Scancell have been ready to go for sometime.
Why are the FDA being such a road block to these trials. I feel so sorry for the many people who would have been given a chance to take part. Some of which may have had their lives extended.

Chester.

It will be interesting to see just how soon the FDA approve Ichor’s device now that we have withdrawn and AZ have submitted there own IND for the use of TriGrid.

Not saying there is a conspiracy against Scancell but interested in the time it now takes to gain full approval. We've been waiting over a year for that approval.
Can AZ make it happen?

Chester.

So it was a clause in the IND submission to the FDA that was preventing the UK arm from starting. Now that IND is withdrawn we can start the UK arm tomorrow if we wanted.

That was my only concern, the fact that we could be further delayed but if we can move ahead with speed I am more than happy that we've sidelined the US trial for now.

Thank you for the clarification.

Chester.

Seeing as nobody answered my question I feel obliged to repost.

With the UK arm of the trial being contingent on the FDA's approval of Ichor’s TriGrid 2, will that device now have to gain approval in the UK or has that process already been dealt with by the UK body that over sees the use of medical devices...?

Chester

This is a prudent question,
With the UK arm of the trial being contingent on the FDA's approval of Ichor’s TriGrid 2, will that device now have to gain approval in the UK or has that process already been dealt with by the UK body that over sees the use of medical devices...?

Chester

Again thank you for that info.

So joining the dots, anyone interested in electroploration as a method of delivery would read all relevent scientific papers including Scancell's SCIB 1 success in using Ichor’s TriGrid.
Therefore in conclusion AZ's scientist would be fully versed in why, how and when Scancell used TriGrid in their trials. But much more importantly, aware or the technique, dose size and results of that trial.
I would think it is fair to say that AZ and the majority of large pharma know all about 'little old Scancell'.

Still poses the difficult to answer question why none ( that we know of ) have stepped forward with a deal...!

Maybe in the next 12 months we will see that happen.

Chester.

Thank you for helping me understand the actual process and why it proves effective.

So back when LD first discovered electroploration and used it in mouse models as a more effective delivery ( or only delivery ) did the Ichor TriGrid 1 exist or was it still at published paper / experimental laborotory stage?

Morning Chaps and Chapesses,

This current conversation about AZ and Ichor’s TriGrid delivery system should be about why use that particular device. I am not as researched as Ray or Inanaco but this is my layman's interpretation of why use TriGrid Electroploration.

Due to the small size of what the scientists are aiming to push into the inside of the targeted cells it is a matter of how the 'drug' is most effectively delivered.

The initial electrical stimulation from the TriGrid creates a localised environment where it is many times more effective to deliver the maximum payload into the patients blood stream.

So it's about what you want to deliver and where you want the 'drug' to be effective.

I hope I've got most of that correct but would appreciate being corrected on any fundamental points I've misinterpreted.

Chester.

Last Sunday I said,

"So is this coming week 'the one', its like waiting for a bus that you know is due any time but you just don't know if the driver turned up for work this week....."

Well the news bus hasn't arrived so far this week. Apparently the driver was seen running off with a stack of news worthy A4 typed sheets of paper but can't be found.
The company are definitely looking for a replacement driver hopefully an American chap.
From a source close to source said "the company now expects the news bus to be arriving very shortly, once there is news of the new driver"

You couldn't write this stuff..... Lol

Chester.

Do you actually know what your talking about. Scancell is a biotech company and not an engineering / manufacturing Co.

Your whole reteric isn't fit for this type of company. You certainly have a grudge on something that we don't understand because you don't ever admit what your agenda is.
Also when we do try to answer your claims with our honest opinion you never respond without being rude. Which actually deminishes you not us.

Chester.